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Background: Epithelial-mesenchymal transition (EMT) plays a crucial role in small airway fibrosis of patients with
chronic obstructive pulmonary disease (COPD). Increasing evidence suggests that the urokinase plasminogen
activator receptor (uPAR) is involved in the pathogenesis of COPD. Increased uPAR expression has been implicated
in the promotion of EMT in numerous cancers; however the role of uPAR in EMT in small airway epithelial cells of
patients with COPD remains unclear. In this study, we investigated the degree of EMT and uPAR expression in lung
epithelium of COPD patients, and verified the effect of uPAR on cigarette smoke extract (CSE)-induced EMT in vitro.
Methods: The expression of EMT biomarkers and uPAR was assessed in lung epithelium specimens from non-smokers
(n = 25), smokers (n = 25) and non-smokers with COPD (n = 10) and smokers with COPD (n = 18). The role of uPAR on
CSE-induced EMT in human small airway epithelial cells (HSAEpiCs) was assessed by silencing uPAR expression in vitro.
Results: Markers of active EMT and uPAR expression were significantly increased in the small airway epithelium of
patients with COPD compared with controls. We also observed a significant correlation between uPAR and vimentin
expression in the small airway epithelium. In vitro, CSE-induced EMT in HSAEpiCs was associated with high expression
of uPAR, and targeted silencing of uPAR using shRNA inhibited CSE-induced EMT. Finally, we demonstrate that the
PI3K/Akt signaling pathway is required for uPAR-mediated EMT in HSAEpiCs.
Conclusions: A uPAR-dependent signaling pathway is required for CSE-induced EMT, which contributes to small
airway fibrosis in COPD. We propose that increased uPAR expression in the small airway epithelium of patients with
COPD participates in an active EMT process.
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Chronic obstructive pulmonary disease and cigarette smokeBackground
Chronic obstructive pulmonary disease (COPD) repre-
sents a major health problem, and is currently the fourth
leading cause of death world-wide [1]. COPD typically
involves two spectra of clinical or pathological presenta-
tion, chronic bronchitis and emphysema. In the majority
of cases, COPD is caused by cigarette smoking, which
induces chronic airway inflammation and development* Correspondence: xiaowei82312@yahoo.cn
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reproduction in any medium, provided the orof emphysema, leading to irreversible airflow limitation
and an accelerated decline in lung function [2]. The
narrowing of small conducting airways before the onset
of emphysematous destruction may explain the in-
creased peripheral airway resistance reported in COPD
[3]. These small airways (< 2 mm in internal diameter)
are major sites of obstruction in patients with COPD.
Studies by Hogg et al. [4] provide the most compelling
evidence that small airways (< 2 mm) undergo remodeling
and fibrous thickening, based on analysis of lung tissues
obtained by cancer resections or lung volume reduction
surgery. The key effector cell in airway fibrogenesis is the
myofibroblast. A detailed understanding of the pathways
underlying myofibroblast proliferation will likely lead totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that may be exploited therapeutically in patients with
COPD.
Airway epithelial cells may acquire a mesenchymal
phenotype and serve as an important source of fibro-
blasts and myofibroblasts, through a process known as
epithelial-mesenchymal transition (EMT) [5]. During
this process, fully differentiated epithelial cells undergo
phenotypic transition to fully differentiated mesenchy-
mal cells, often fibroblasts and myofibroblasts. The
interaction between EMT and airway epithelial cells has
been addressed by several in vitro studies. Molloy et al.
were the first to report an EMT process in airway epi-
thelial cells (AECs), following the demonstration that
BMP4 induces EMT in human bronchial epithelial cells
[6]. McCormack and colleagues proposed that acquisi-
tion of an EMT-like phenotype by AECs is a normal as-
pect of wound repair. Furthermore, they suggest that
diseases involving fibrosis may arise because the EMT
phase of repair is prolonged by chronic injury/inflamma-
tion [7]. Recent studies have shown that cigarette smoke
condensate (CSC) induces an EMT-like process in hu-
man bronchial epithelial cells (BEAS-2B) [8], however
the effect of cigarette smoke on EMT of small airway
epithelial cells is currently poorly understood. Sohal
et al. provide evidence that EMT is indeed an active
process in the airways of smokers, particularly in those
of current-smoking COPD patients. This was based on
immunohistochemical analysis of epithelial and mesen-
chymal markers in the basal layer of the epithelium and
in the fragmented reticular basement membrane (Rbm)
[9]. Active airway EMT in COPD patients may be re-
lated to subsequent fibrotic activity in the sub-epithelial
tissue, however the mechanisms involved in this process
remain to be elucidated.
Our group previously demonstrated that urokinase plas-
minogen activator receptor (uPAR) is highly expressed in
the small airway epithelia of patients with COPD com-
pared with normal controls [10]. Furthermore, uPAR ex-
pression was also related to clinical parameters of airflow
limitation. The uPAR protein is a modulator of the
plasminogen pathway, which cleaves and activates
urokinase-type plasminogen activator (uPA) [11]. uPAR-
uPA is involved in the proteolytic activation of plasmino-
gen to plasmin, which in turn degrades fibrin and other
extracellular matrix (ECM) components and activates
matrix metalloproteases. Given the known biology of
uPAR, this receptor may be implicated in small airway re-
modeling in COPD, leading to the eventual decline in lung
function. In support of this, studies by Lester et al. [12]
demonstrated that uPAR activates diverse cell signaling
pathways, including ERK/MAPK, Rac1, Akt and glycogen
synthase kinase-3β (GSK-3β), that cooperatively induce
EMT in hypoxic breast cancer cells.Although the role of uPAR in small airway disease has
previously been evaluated in COPD, the role of uPAR in
active EMT in the small airways of COPD patients re-
mains unknown. In this study, we characterized mesen-
chymal marker expression in small airway epithelial cells
of COPD patients. In addition, because cigarette smoke
exposure is associated with COPD pathogenesis, we in-
vestigated cigarette smoke extract (CSE)-induced EMT
in human small airway epithelial cells and examined the
effects of uPAR on this process in vitro. Our study indi-
cates that uPAR expression is related to EMT in human
small airway epithelium, demonstrating a critical role for
uPAR in COPD pathogenesis.
Methods
Patients
Lung tissues were obtained from 78 patients (25 non-
smokers, 25 smokers without COPD, 10 non-smokers
with COPD and 18 smokers with COPD) at Qilu
Hospital (Jinan, China) following lobectomy or pneu-
monectomy for various medical reasons. The diagnosis
of COPD was made according to the guidelines of the
Global Initiative for Chronic Obstructive Lung Disease
[13]. No subjects received corticosteroids (oral or in-
haled) prior to tissue collection. All experiments were
approved by the ethics committee of Qilu Hospital and
informed consent was obtained from all patients prior to
specimen collection.
Immunohistochemistry
Serial sections (4 μM) of formalin-fixed, paraffin-embedded
lung tissue were used for immunohistochemical analysis.
Sections were immunostained with primary antibodies
recognizing E-cadherin (24E10, Cell Signaling Tech-
nology, Beverly, MA, USA), vimentin (D21H3, Cell
Signaling Technology) and uPAR (10G7, Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and visualized
using the avidin-biotin-peroxidase (ABC) complex
(ZhongShan Biotech, Beijing, China) method. Color
development was performed using a DAB color devel-
opment kit (ZhongShan Biotech). Images were cap-
tured using an OLYMPUS IX81 light microscope
(Olympus, Tokyo, Japan) fitted with a SPOT camera.
Image analysis was performed using Image-Pro Plus
6.0 software (Media Cybernetics, Silver Spring, MD,
USA). All slides were analyzed in a single batch by a
single experienced observer with quality assurance on
randomly selected slides provided by a professional
academic pathologist.
Preparation of CSE
CSE was prepared using a modified method described
by Aoshiba [14]. Briefly, one filterless commercial
cigarette (13 mg of tar and 1.2 mg of nicotine per
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apparatus. Mainstream smoke was bubbled through 20 ml
of serum-free Ham‘s F12 nutrient medium (F12). The
resulting suspension was adjusted to pH 7.4 with concen-
trated NaOH and filtered through a 0.22-μm pore filter to
remove bacteria and large particles. This solution (desig-
nated as a 100% CSE solution) was used within 30 min of
preparation.
Cell culture
Human small airway epithelial cells (HSAEpiCs) were
obtained from ScienCell Research Laboratories (Cat. No.
3231). Cells were cultured in Small Airway Epithelial
Cell Medium (SAEpiCM) at 37°C in a water-saturated
atmosphere with 5% carbon dioxide.
uPAR-specific short hairpin RNA inhibition
For knockdown of uPAR expression in HSAEpiCs, short
hairpin RNAs (shRNAs) targeting human uPAR
(shuPAR1, GCCGTTACCTCGAATGCAT and shuPAR2,
GGUGAAGAAGGGCGUCCAA) were cloned into the
pSuper vector as previously described [15]. Control oligo-
nucleotides corresponding to the inverse uPAR shRNA
sequences were also prepared. Sub-confluent (75%) cell
monolayers were transfected with pSuper-shRNA
targeting uPAR or empty vector using Lipofectamine
2000 (Invitrogen, Carlsbad, CA, USA), in accordance
with the manufacturer’s instructions. After 24 h, cells
were trypsinized and subjected to various experiments.
uPAR knockdown was assessed by real-time-polymerase
chain reaction (PCR) and western blotting.
Real-time PCR
Total RNA was extracted using Trizol reagent (Invitrogen)
according to the manufacturer‘s instructions. First strand
cDNA was synthesized using Superscript II reverse tran-
scriptase (Invitrogen). Real-time PCR reactions were pre-
pared using SYBR® Green Real time PCR Master Mix
(Invitrogen) and PCR was performed with an ABI PRISM
7900 HT Sequence Detection System. Primers used
for the amplification of indicated genes are listed in
Additional file 1: Table S1. Endogenous GAPDH was
used as a normalization control. Relative quantifica-
tion of mRNA was performed using the comparative
CT method [16].
Western blot analysis
Cells extracts were prepared using ice-cold RIPA buffer
(20 mM sodium phosphate, 150 mM NaCl, pH 7.4, 1%
NP-40, 0.1% SDS and 0.5% deoxycholic acid) containing
complete protease inhibitor cocktail (Roche) and 1 mM so-
dium orthovanadate. Proteins were separated by 10% SDS-
PAGE and transferred to PVDF membranes and probed
with antibodies detecting human uPAR, E-cadherin,α-catenin (610194, BD Transduction Laboratories),
N-cadherin (610920, BD Transduction Laboratories),
α-SMA (324316, Santa Cruz), phospho-Akt (#4060,
Cell Signaling Technology), Akt (#4691, Cell Signal-
ing Technology), Snail (10433, Santa Cruz), phospho-
GSK-3β (81494, Santa Cruz) and GSK-3β (53931,
Santa Cruz). β-actin (#4970, Cell Signaling Technology)
was used as an endogenous loading control.
Statistical analysis
Patient’s age, clinical score and real time PCR expression
data are expressed as the mean ± standard deviation.
The Kruskal–Wallis and Mann–Whitney U-test were
used for comparisons between patient groups. The
Spearman test was used for correlation analyses. Stu-
dent’s t test was used for in vitro experiments on




Demographic characteristics and functional evaluation of
the patient study groups are shown in Table 1. All patient
groups exhibited a similar age range. The forced expiratory
volume (FEV1%) of predicted and the FEV1/forced vital
capacity (FVC) ratio were significantly lower in patients
with COPD compared with control subjects (P < 0.01). In
contrast, we observed no difference in FEV1% of predicted
or in the FEV1/FVC ratio between smokers with COPD
and non-smokers with COPD (P > 0.05).
EMT in patient small airway epithelium cells
Thickening of the walls of small airways is caused by fi-
brosis and infiltration of inflammatory cells [17]. Be-
cause EMT is associated with fibrosis, we first assessed
the expression of EMT biomarkers in distal airway epithe-
lial cells from patients with lung resection. Expression of
the epithelial marker, E-cadherin and the mesenchymal
marker, vimentin was assessed in small airway epithelium
from a non-smoker and a patient with COPD by immuno-
histochemistry (Figure 1A). We observed significant im-
munostaining of E-cadherin in small airway epithelial cells
from a non-smoker, while vimentin expression was absent.
In contrast, E-cadherin was expressed at lower levels in
the small airway epithelium of a patient with COPD, while
vimentin was detected in the distal airway epithelium. A
marked increase in the number of vimentin positive cells
was observed within the small airway epithelium of
smokers with COPD, non-smokers with COPD and
smokers compared with non-smokers without COPD
(Figure 1B), especially in patients with COPD. In contrast,
we observed no significant difference in the number of
vimentin positive cells between smokers with COPD and
non-smokers with COPD (P =0.4493; Figure 1C).
Figure 1 Immunohistochemistry for EMT biomarkers in small airways epithelium of patients with chronic obstructive pulmonary
disease (COPD). Small airways sections from non-smokers (n = 25), smokers (n = 25), non-smokers with COPD (n = 10), and smokers with COPD
(n = 18) were immunostained. (A) Epithelial marker E-cadherin (brown) and mesenchymal marker vimentin (brown) staining are observed in small
airways epithelium from a non-smoker and a patient with COPD with serial sections. Black arrows show the main distribution of the positive
immunostaining regions. (B) Mesenchymal marker vimentin (brown) from non-smokers (a), smokers (b), non-smokers with COPD (c) and smokers
with COPD (d). (C) Quantification of mesenchymal marker vimentin positive cells in the small airways epithelium. The number of positive
epithelial cells per mm reticular basement membrane (Rbm) in small airways. P values in figure were obtained by Mann–Whitney U test analyses.
Images were obtained using a 100 × oil-immersion objective.
Table 1 Demographic characteristics of the subjects
Non-smokers(NC) n = 25 Smokers (NS) n = 25 Non-smokers with COPD (CN) n = 10 Smokers with COPD (CS) n = 18
Sex (female/male) 20/5 1/24 9/1 0/18
Age (years) 55 ± 9 56 ± 11 59 ± 7 61 ± 9
Smoking history,
pack-years
― 26 ± 14 ― 37 ± 25
FEV1,% predicted 97 ± 15 99 ± 11 65 ± 17 70 ± 16
FEV1/FVC% 84 ± 8 80 ± 7 56 ± 7 61 ± 5
GOLD stage
1 ― ― 1 1
2 ― ― 7 12
3 ― ― 2 5
4 ― ― ― ―
Values are given as mean ± SD.
Pack-year = 1 year smoking 20 cigarettes per day.
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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To investigate whether EMT in the small airways of
COPD may be explained by an increase in uPAR, we
next investigated uPAR expression in human lung tis-
sues. Our previous study confirmed that uPAR expres-
sion was significantly elevated in the small airway
epithelia of subjects with COPD (n = 16) compared with
control subjects [10]. In this study, we assessed uPAR
expression by immunostaining in small airway epithelial
cells in a larger patient cohort (Figure 2A). The expres-
sion of uPAR in small airway epithelial cells was assessed
using the mean staining density calculated using Image-
Pro Plus 6.0. uPAR expression was increased in the
epithelium of distal airways from smokers and patients
with COPD, compared with non-smokers. Moreover, weFigure 2 Urokinase plasminogen activator receptor (uPAR)
immunostaining in small airways epithelium of patients with
COPD. (A) uPAR staining in the epithelium of small airways from
non-smokers (a), smokers (b), non-smokers with COPD (c) and
smokers with COPD (d) (original × 200). (B) Quantification of uPAR
protein levels in the small airways epithelium. The mean staining
density in small airways.observed a significant increase in uPAR levels in the epi-
thelium of patients with COPD compared with non-
smokers and smokers (P < 0.01; Figure 2B). There is no
significant difference in uPAR levels between smokers
with COPD and non-smokers with COPD (P > 0.05;
Figure 2B).
Correlation analysis
We next investigated whether uPAR or vimentin expres-
sion in the small airways correlated with FEV1% of pre-
dicted. The severity of postbronchodilator FEV1% of
predicted is recommended for the diagnosis and assess-
ment of COPD severity according to the Global Initia-
tive for Chronic Obstructive Lung Disease (GOLD). We
also evaluated the relationship between uPAR and
vimentin expression in the epithelium of distal airways.
We observed a significant inverse correlation between
FEV1% and uPAR expression (r = −0.564, P < 0.01,
Figure 3A) and vimentin expression (r = −0.461, P < 0.01,
Figure 3B). A significant correlation between the mean
staining density of uPAR and the number of vimentin
positive cells (per mm basal membrane) in the small air-
way epithelium was also observed (r =0.701, P < 0.01,
Figure 3C).
CSE-induced EMT in cultured HSAEpiCs
Cigarette smoking is the most commonly encountered
risk factor for COPD. To better model this microenvir-
onment, we cultured HSAEpiCs in the presence of CSE.
Following treatment with 5% CSE for 48 h, HSAEpiCs,
which typically appear epithelial with well-developed cell
junctions, acquired a spindle shape and exhibited a gen-
eral loss of cell contact (Figure 4A).
To examine whether CSE induces EMT in HSAEpiCs,
cells were exposed to 5% CSE for various time points.
The expression of E-cadherin and α-catenin epithelial
markers was significantly decreased in HSAEpiCs at
both mRNA and protein levels in response to 5% CSE,
in a time-dependent fashion. In contrast, CSE increased
the expression of N-cadherin and α-smooth muscle actin
(α-SMA) mesenchymal markers in HSAEpiCs in a time-
dependent manner (Figure 4B, C).
CSE-induced uPAR signaling pathway activation in
cultured HSAEpiCs
To further investigate the role of cigarette smoke expos-
ure in EMT, we evaluated the expression of uPAR in
CSE stimulated HSAEpiCs at both mRNA and protein
levels. Expression of UPAR mRNA was markedly in-
creased in a time-dependent manner following CSE ex-
posure, reaching peak levels after 72 h (Figure 4D).
Treatment of cells with CSE also led to a significant in-
crease in uPAR protein expression in a time-dependent
manner (Figure 4E).
Figure 3 Correlations between the expression of uPAR or mesenchymal marker vimentin positive cells in small airways and functional
parameters. (A) The expression of uPAR in small airways of 78 subjects was correlated with FEV1% of predicted, as an index of airflow
obstruction severity in COPD. (B) Mesenchymal marker vimentin positive cells per mm in small airways was correlated with FEV1% of predicted.
(C) The expression of uPAR in small airways was correlated with vimentin positive cells per mm.
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To further investigate the requirement for uPAR in CSE-
induced EMT, we performed targeted knockdown of
uPAR in HSAEpiCs using the shRNA silencing vector,
pSuper-shuPAR. We established two knockdown clones
(shuPAR1 and shuPAR2) expressing small and negligible
levels of uPAR protein. Inhibition of uPAR expression in
individual clones compared with empty vector trans-
duced cells was confirmed by real-time PCR and western
blot (P < 0.01, Figure 5A, B). Analysis of morphological
changes following treatment of cells with 5% CSE for
72 h revealed that uPAR knockdown (shuPAR2) caused
a decrease in the population of spindle shaped cells
(Figure 5C).
To test whether uPAR is responsible for CSE-induced
EMT, we examined the expression of several epithelial and
mesenchymal marker proteins by western blotting. CSE-
treated control vector HSAEpiCs exhibited loss of cell sur-
face E-cadherin and α-catenin, whereas N-cadherin and
α-SMA were clearly detected, in keeping with the
changes observed with parental cells. In contrast, CSE-
treated shuPAR2 cells exhibited increased E-cadherinand α-catenin and decreased N-cadherin and α-SMA
expression (Figure 5D).
PI3K/Akt signaling pathway is required for uPAR-
mediated EMT in HSAEpiCs
We hypothesized that activation of uPAR-dependent cell
signaling may be responsible for the molecular and mor-
phological changes observed in HSAEpiCs in response
to CSE treatment. Recent studies indicate that the PI3K-
Akt pathway is activated by uPA binding to uPAR
[18,19]. Indeed, inhibition of PI3K/Akt signaling using
the PI3K/Akt inhibitor, LY294002, impaired uPAR mor-
phogenic activity [20-22]. To test this hypothesis, we
examined base-line levels of Akt activation in HSAEpiCs
cultured in 5% CSE for 72 h by western blot. We observed
a significant increase in phosphorylated Akt (p-Akt) in
CSE-treated HSAEpiCs (Figure 6A).
To determine whether uPAR is necessary for Akt acti-
vation in CSE-treated HSAEpiCs, we tested the effect of
uPAR gene silencing on Akt activation. Western blot
analysis revealed activation of PI3K-dependent Akt
phosphorylation in parental cells and cells transduced
Figure 4 Cigarette smoke extract (CSE) induces epithelial-mesenchymal transition and increases uPAR levels in cultured human
small airway epithelial cells (HSAEpiC). (A) Cells were cultured for variable time points with 5% CSE. Cell images were captured by phase-
contrast microscopy. (B) Epithelial markers E-cadherin and α-catenin, mesenchymal markers N-cadherin and α-smooth muscle actin (α-SMA)
mRNA levels were determined by Real-time PCR (mean ± SEM; n = 3). (C) Epithelial markers E-cadherin and α-catenin, mesenchymal markers
N-cadherin and α-SMA protein levels were determined by Western blot. The original extracts were subjected to Western blot analysis for
β-actin, as a loading control. (D) UPAR mRNA level was determined by Real-time PCR (mean ± SEM; n = 3). (E) uPAR protein level was
determined by Western blot.
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trast, the level of phosphorylated Akt was substantially
inhibited in shuPAR2 cells cultured with CSE compared
with controls (Figure 6B).
During EMT, Akt-induced GSK-3β phosphorylation
leads to GSK-3β inactivation. GSK-3β regulates Snail ac-
tivity by inhibiting Snail expression, promoting Snail
degradation and decreasing nuclear localization. Control
cells treated with 5% CSE exhibited EMT at 72 h coin-
ciding with upregulation of GSK-3β phosphorylation and
Snail protein levels. Treatment of cells with 10 μM
LY294002 blocked the induction of GSK-3β phosphoryl-
ation, Snail and α-SMA (Figure 6C). LY294002 also
preserved expression of the epithelial cell marker E-
cadherin in HSAEpiCs treated with CSE. These results
suggest that uPAR-dependent Akt activation is essential
for CSE-induced EMT.Discussion
In this study, we demonstrate for the first time that uPAR
is a regulator involved in the EMT process in the small
airways of patients with COPD. Our results demonstrate a
significant increase in uPAR expression levels and in the
degree of active EMT in the small airway epithelium of
patients with COPD compared with non-smokers and
smokers with normal lung function. Furthermore, we ob-
served a significant correlation between uPAR expression
and EMT in the small airway epithelium of COPD pa-
tients. CSE-induced EMT in cultured HSAEpiCs was ac-
companied by significant induction of uPAR expression,
and targeted silencing of uPAR by shRNA inhibited
CSE-induced EMT. Taken together, these data suggest
that uPAR plays a critical role in CSE-induced EMT.
In addition, we demonstrate that the PI3K/AKT signal-
ing pathway is required for uPAR-mediated EMT in
Figure 5 uPAR is required for CSE-induced EMT in HSAEpiC cells. (A) Cells expressing empty vector, shuPAR1 cells, and shuPAR2 cells were
cultured for 24 h. UPAR mRNA was determined by Real-time PCR (mean ± SEM; n = 3). (B) uPAR protein level was determined by Western blot. (C)
Empty vector and shuPAR2 cells were cultured for 72 h with 5% CSE. Cell images were captured by phase-contrast microscopy. (D) Parental cells,
empty vector and shuPAR2 cells were cultured for 72 h without or with 5% CSE. Cell extracts were subjected to Western blot analysis for
epithelial markers E-cadherin and α-catenin, mesenchymal markers N-cadherin and α-SMA. β-actin was used as a loading control.
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uPAR participates in the EMT process in the small air-
way epithelium of patients with COPD.
COPD is characterized by airflow limitation that is not
completely reversible. Reduced FEV1 characterizes air-
flow limitation in COPD, and likely occurs because of
small airway disease [23]. Hogg and colleagues showed
that obstruction of the small airways in COPD is associ-
ated with thickening of the airway wall via remodeling
processes related to tissue repair [24]. Fibrosis of the
small airways is caused by impaired repair followinginjury to the bronchiolar epithelium [25]. To date, how-
ever, the exact mechanisms underlying small airway re-
modeling in COPD remain poorly understood. EMT is
associated with tissue regeneration and fibrosis. EMT re-
fers to a series of phenotypic and molecular changes that
occur during various steps of embryonic development,
but also in the development of fibrosis and cancer pro-
gression. Epithelial cells, via EMTs, are as important pre-
cursors of the fibroblasts and myofibroblasts that arise
during the course of fibrosis [26]. Although EMT in the
airways is implicated in COPD pathogenesis, the
Figure 6 PI3K/Akt signaling pathway is required for uPAR-mediated EMT in HSAEpiC Cells. (A) Cells were cultured for 72 h without or with
5% CSE. Cell extracts were subjected to Western blot to detect phosphorylated Akt and total Akt. (B) Parental cells, empty vector and shuPAR2
cells were cultured for 72 h without or with 5% CSE. Cell extracts were subjected to Western blot analysis for phosphorylated Akt (p-Akt),
phosphorylated GSK-3β (p-GSK-3β), Snail, and β-actin. (C) Cells were treated with 10 μM of the PI3K inhibitor LY294002 or with vehicle (control)
for 72 h without or with 5% CSE. Cell extracts were subjected to Western blot analysis to detect p-Akt, p-GSK-3β, Snail, E-cadherin, α-SMA and
β-actin (representative of three studies).
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tients with COPD remain poorly unclear.
Sohal et al. recently observed potential activation of an
EMT program in large airways taken from endobronchial
biopsies of smokers and patients with COPD [27]. It
should be noted, however, that airway remodeling in
COPD is mainly located in small conducting airways, and
that large and small airways differ in their anatomical and
pathophysiological characteristics. Taking this into account,
Milara et al. used primary human bronchial epithelial cells
(HBECs) from small human bronchi of nonsmokers,
smokers and patients with COPD. They showed that the
EMT process was present in bronchial epithelial cells of
the small bronchi of smokers and patients with COPD and
was activated by cigarette smoke in vitro [28]. Although
this study demonstrated that cigarette smoke may induce
EMT by modulating the TGF-β1 pathway as well as ROS
and cAMP levels in primary HBECs, the molecular mecha-
nisms of EMT in the epithelial cells of small airways in
COPD patients are still unclear. Previously, Wang et al.
identified uPAR expression as an important factor in the
progression of COPD by pathway analysis of a signature
set of 203 differentially regulated genes [29]. We also
showed that uPAR, which can promote EMT in several
tumor cell systems [30-32], is highly expressed in the small
airway epithelium of patients with COPD compared with
controls [10]. However, to date, the role of active EMT in
small airways of patients with COPD remains unknown.
We first assessed the expression of EMT biomarkers
by immunostaining in small airway epithelial cells frompatients with lung resection. We observed significant ex-
pression of the epithelial marker, E-cadherin, in the
small airway epithelium of non-smokers while vimentin
expression was nearly absent. In contrast, E-cadherin
was expressed at lower levels in the small airway epithe-
lium of smokers and patients with COPD; however
vimentin was clearly observed within the distal airway
epithelium. We also observed a marked increase in the
number of vimentin positive staining cells within the
small airway epithelium of patients with COPD; however
no difference was seen in the number of vimentin posi-
tive cells between smokers with COPD and nonsmokers
with COPD. From the above results, we conclude that
cigarette smoke is not the only major factor promoting
active EMT, but that other risk factors contribute to
airway EMT in COPD. Subsequently, we assessed
uPAR expression in small airway epithelial cells in a
large patient cohort. uPAR expression was increased in
the epithelium of distal airways from smokers and pa-
tients with COPD compared with nonsmokers, espe-
cially in patients with COPD, in keeping with our
previous study [10]. Furthermore, we observed a sig-
nificant inverse correlation between FEV1% and uPAR
or vimentin expression. A significant correlation was
also observed between the uPAR expression and
vimentin positive cells (per mm of basal membrane) in
the small airway epithelium. These results indicate that
increased uPAR levels may promote EMT in small air-
ways, thus accounting for the previously observed re-
duced capacity in COPD patients.
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cause of its relevance in the pathogenesis of COPD. We
also used this model to investigate mechanisms underlying
EMT in COPD. Treatment of HSAEpiCs with CSE led to
the acquisition of a fibroblast-like morphology and general
loss of cell contacts. This was accompanied by the
downregulation of epithelial markers such as E-cadherin
and α-catenin, and simultaneous upregulation of mesen-
chymal markers such as N-cadherin and α-SMA. The
levels of uPAR mRNA and protein were markedly in-
creased after exposure of HSAEpiCs to CSE. To test
whether uPAR is responsible for CSE-induced EMT, we
suppressed uPAR expression using shRNA. This led to in-
hibition of CSE-induced EMT in HSAEpiCs, indicating
that uPAR is required for CSE-induced EMT in HSAEpiC.
Several cell signaling factors have been implicated in
this active EMT process. PI3K/Akt is known to promote
EMT by regulating the activity of GSK3β, which targets
Snail for degradation by suppressing NF-κB-dependent
Snail expression [33,34]. The activities of GSK3β limit
the ability of Snail to function as an E-cadherin tran-
scriptional repressor [35]. Other oncogenes, including
Rac1, c-Src and Ras have also been implicated in the
EMT process [36-38]. Because PI3K/Akt, Rac1, c-Src
and Ras are all activated downstream of uPAR [39], we
therefore favor a model in which CSE-induced uPAR ex-
pression activates cell signaling via diverse pathways that
are complementary in inducing the full spectrum of cel-
lular changes observed in EMT.
To test this model, we studied a uPAR-dependent cell
signaling pathway in HSAEpiCs. We showed that PI3K/
Akt is activated in HSAEpiCs following treatment with
CSE, and this response was blocked by silencing uPAR.
Treatment of cells with the PI3K inhibitor, LY294002,
also inhibited CSE-induced GSK3β phosphorylation and
Snail expression and preserved cell surface E-cadherin.
Our finding that uPAR regulates PI3K/Akt activity, and
consequently inhibits GSK3β activity, suggests that the
uPAR pathway may also contribute to various functions/
phenotypes modulated by PI3K/Akt and GSK3β. In our
study, the effect of uPAR on EMT via regulation of a
PI3K/Akt/GSK3β signaling module is very significant.
The link between uPAR and Akt activation by CSE pro-
vides one mechanism by which uPAR may ultimately
regulate Snail expression and thus promote EMT.
Conclusions
In summary, we demonstrated that uPAR is overexpressed
in the distal airways of COPD patients, and this correlates
with the degree of airflow obstruction and EMT activation
of small airway epithelial cells. We also demonstrated that
CSE induces diverse molecular and phenotypic changes in
HSAEpiCs that are consistent with EMT. Furthermore,
we showed that cell signaling factors previously shown tobe involved in EMT, including PI3K/Akt, GSK-3β and
Snail, are activated in CSE-induced HSAEpiCs. These
EMT-associated molecular and phenotypic changes are
due to CSE-induced uPAR expression and activation of
uPAR dependent cell signaling. We conclude that EMT
may be induced in the small airway epithelium of patients
with COPD, via a mechanism that involves activation of
uPAR-dependent cell signaling.
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